PUBLIC COMPANY
save$GPCRStructure Therapeutics Inc.
$GPCR27.67-4.52%South San Francisco, CA, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (2)
- Apr 15, 26grantLang Matthew · COO & GC184,614 sh
- Apr 15, 26grantLang Matthew · COO & GC223,776 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…endpoints · 25d ago
- Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropStructure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s…biospace · 25d ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 1mo ago
- Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical modelsEfficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on…biospace · 1mo ago
- Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO→ Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer. On April 1, 2027, the Japanese pharma will split the com…endpoints · 1mo ago
- Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateCurrent leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…biospace · 1mo ago
- Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.biospace · 1mo ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 1mo ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 1mo ago
- #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six monthsThe race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...endpoints · 3mo ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that